AstraZeneca PLC / Arrow Therapeutics Ltd.

Respiratory Syncytial Virus (RSV) infection

80K US cases/yr

Disease Overview

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in infants and a major cause of severe disease in older adults and immunocompromised patients. Before recent prevention products, ~58,000-80,000 children under 5 were hospitalized in the US each year and 100,000-160,000 adults 60+ are hospitalized annually (CDC).

Competitive Landscape

In 2007 there were no approved oral small-molecule RSV antivirals; standard of care was supportive plus MedImmune's monoclonal Synagis (palivizumab) for high-risk infants. AstraZeneca's $150M cash acquisition of Arrow Therapeutics (closed March 2 2007) brought in RSV604, a Phase II oral small molecule partnered with Novartis, plus two NS5A-targeted HCV candidates (one in Phase I) and a London-based 57-person discovery team (FierceBiotech, GenEngNews). Strategically the deal aligned with AstraZeneca's stated re-focus on infection and anti-bacterials and was framed as building a self-contained antiviral hub rather than absorbing Arrow into AZ's main R&D structure. The deal mattered because RSV represented one of the largest unmet needs in respiratory medicine and a successful oral antiviral would have rivaled Synagis economics. RSV604 ultimately failed to advance, and the broader RSV market was reshaped a decade later by AstraZeneca/Sanofi's Beyfortus (nirsevimab) monoclonal and the Pfizer Abrysvo and GSK Arexvy adult vaccines (2023 approvals).